Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Interventional Open-label, Single-group, Phase I/II Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Adult Patients With Relapsed or Refractory Forms of B-cell Lymphoproliferative Disorders

NCT06705530 is registered in ClinicalTrials.gov with National Research Center for Hematology, Russia as lead sponsor.

NCT NCT06705530
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06705530 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Interventional Open-label, Single-group, Phase I/II Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Adult Patients With Relapsed or Refractory Forms of B-cell Lymphoproliferative Disorders
Lead sponsor
National Research Center for Hematology, Russia
Phase
Phase 1/2
Overall status
Completed
Start date
November 26, 2024
Completion date
November 17, 2025
Enrollment
58 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia all, non-hodgkin lymphoma, b-cell